{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.2","upperLimit":"21.4","value":"15.3"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"14.8","value":"9.5"},{"groupId":"OG002","lowerLimit":"7.7","upperLimit":"19.6","value":"13.6"}]}],"title":"% Work Time Missed at Baseline (n=66,63,67)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.3","upperLimit":"8.2","value":"0.4"},{"groupId":"OG001","lowerLimit":"-4.5","upperLimit":"4.5","value":"-0.0"},{"groupId":"OG002","lowerLimit":"-13.0","upperLimit":"4.6","value":"-4.3"}]}],"title":"Change in % Work Time Missed (n=35,33,36)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.1","upperLimit":"25.9","value":"20.0"},{"groupId":"OG001","lowerLimit":"9.5","upperLimit":"21.1","value":"15.3"},{"groupId":"OG002","lowerLimit":"13.6","upperLimit":"26.1","value":"19.9"}]}],"title":"% Impairment While Working at Baseline(n=67,64,67)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"15.6","value":"8.8"},{"groupId":"OG001","lowerLimit":"-11.0","upperLimit":"10.5","value":"-0.3"},{"groupId":"OG002","lowerLimit":"-11.0","upperLimit":"5.2","value":"-2.7"}]}],"title":"Change in % Impairment While Working (n=34,32,35)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.7","upperLimit":"36.2","value":"28.5"},{"groupId":"OG001","lowerLimit":"13.8","upperLimit":"28.7","value":"21.2"},{"groupId":"OG002","lowerLimit":"20.3","upperLimit":"35.9","value":"28.1"}]}],"title":"% Overall Work Impairment at Baseline (n=65,62,66)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.4","upperLimit":"18.6","value":"9.1"},{"groupId":"OG001","lowerLimit":"-13.0","upperLimit":"11.0","value":"-1.1"},{"groupId":"OG002","lowerLimit":"-14.0","upperLimit":"5.0","value":"-4.6"}]}],"title":"Change in % Overall Work Impairment (n=34,31,35)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"67"}],"units":"Participants"}],"description":"The WPAI is a patient-reported measure which assesses the effect of general health and symptom severity on work productivity and regular activities. The General Health questionnaire asks participants to estimate the number of hours missed from work due to reasons related and unrelated to their health problems, as well as the total number of hours actually worked in the preceding 7-day period. The percentage of participants reporting that they were employed (working for pay) was assessed at baseline was assessed along with Absenteeism (work time missed), Presenteeism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. The reported changes represent change from baseline at Cycle 7. The score range for the scales of the WPAI is between 0 (no effect) to 100% (max effect)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"MEAN","populationDescription":"Number of participants analysed=participants from ITT population who were employed at baseline. Here, 'n' signifies the number of participants with available data at specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 7 (Week 18)","title":"Change From Baseline in Work Productivity According to Work Productivity and Activity Impairment (WPAI) Questionnaire Score","type":"SECONDARY","unitOfMeasure":"percent of work"}